MSCs, lncRNA and miRNA in HER2-negative breast cancer treatment have important application value (159), in addition, the new technology such as nanometers provides a new drug delivery system, which can improve drug efficacy and reduce drug side effects at the same time. Here, ERBB2 is linked to breast carcinoma.